Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q1 2020 · 10-Q
Revenue—
Net Income$2.90M$2.90MN/M vs Q1 2019 EPS Diluted$0.89$0.89N/M vs Q1 2019 Operating Income-$7,622,000N/M Operating Cash Flow-$11,175,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
ended Mar 31, 2020 · filed May 13, 2020 · 43 d after period end